A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol

COVID-19 Infection Clinical Trial

— AeroVax  

Official title:

A Phase 2 Trial to Evaluate Safety and Immunogenicity of a Next-generation COVID-19 Vaccine Delivered by Inhaled Aerosol to Humans

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06381739
• Other study ID #: M011
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 2024
• Est. completion date: July 2026

Study information

• Verified date: April 2024
• Source: McMaster University
• Contact: Marilyn Swinton
• Phone: 289-244-3997
• Email: swinton[@]mcmaster.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine).

To be in the study participants will have to have already had three doses of a messenger ribonucleic acid (mRNA) COVID vaccine and be generally healthy. Participants are given a single dose of the vaccine by breathing in a fine mist that goes directly into the lungs.

During follow-up participants will:

• visit the clinic for checkups and blood tests at 2, 4 and 8 weeks after vaccination

• report their symptoms for 24 weeks after getting the vaccine.

In some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy).

Description:

The global impact of the coronavirus disease 2019 (COVID-19) pandemic remains profound; COVID-19 continues to be one of the leading causes of death and hospitalization due to infectious disease, disproportionately affecting the elderly and immunocompromised. The continuous evolution of the virus has significantly challenged the effectiveness of first-generation and updated vaccination strategies. These variants of concern (VOCs) can evade neutralizing antibodies.

Adequate and early lung mucosal immunity is critical for control of infection but current vaccines fail to induce robust mucosal immunity in the lungs, a major reason for the high rates of break-through infections. The respiratory mucosal route of immunization, however, can induce protective respiratory mucosal immunity consisting of trained innate immunity (via memory airway macrophages), mucosal antibodies, and tissue-resident memory CD4+/CD8+ T cells.

A phase 1 study has been completed using a recombinant chimpanzee adenovirus (ChAd) vector, ChAd-CoV3/Mac in 23 healthy volunteers and has shown that the vaccine can be safely administered by aerosol and that immune responses against COVID-19 develop in the lung and T-cells and neutralizing antibodies are generated in the blood.

The purpose of this placebo-controlled Phase 2 trial is to determine if this new COVID-19 vaccine, ChAd-triCoV/Mac, is safe to give by aerosol to people who have been vaccinated with at least three doses of a COVID mRNA vaccine and evaluate the immune responses generated. Specifically, the researchers want to see if T cell responses and antibody responses to the COVID virus proteins develop in the blood after receiving the vaccine.

There is a lack of surrogate immune markers for vaccine-induced protection against antibody-evading VOCs of SARS-CoV-2. However, given the now recognized importance of respiratory mucosal T cell immunity in anti-SARS-CoV-2 host defense, this study will allow for a correlation of mucosal T cell immunity with the T cells in blood to help predict vaccine efficacy, and inform the design of phase 3 efficacy studies.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 350
• Est. completion date: July 2026
• Est. primary completion date: July 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

1. Adults who are 18-65 years old on the day of randomization (day 1)

2. Able to read, write and communicate using the English or French language.

3. Received at least 3 doses of an mRNA COVID vaccine.

4. Individuals of childbearing potential must have a negative pregnancy test prior to vaccination and be willing to practice effective contraception for 8 weeks post-vaccination.

5. Able to understand and comply with protocol requirements and instructions; able to report adverse events; able to attend scheduled study visits and complete required investigations.

6. For participants in the BAL sub-study, Complete Blood Count (CBC) and chemistry (creatinine) within normal limits.

7. For participants in the BAL sub-study, forced expiratory volume in 1 second (FEV1) > the lower limit of normal (LLN), and FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity) ratio above the LLN.

8. Agree not to enroll in any other intervention studies for the duration of the study where the intervention could be reasonably expected to be associated with adverse events overlapping with the inhaled vaccine or the immune responses being measured.

Exclusion criteria:

1. Failure to provide informed consent.

2. Women who are pregnant or breastfeeding.

3. Have received any recombinant adenoviral-vectored COVID-19 vaccine (AstraZeneca [Vaxzeria] or Johnson & Johnson (Janssen Jcovden).

4. COVID infection (positive PCR or antigen (Ag) test, self-reported or lab documented) within the last 90 days.

5. Last dose of a COVID vaccine administered less than 90 days prior to study entry.

6. Administration of any vaccine within 2 weeks of study entry.

7. Active pulmonary disease diagnosed by a physician including asthma, chronic bronchitis, interstitial lung disease, pulmonary hypertension, lung cancer, cystic fibrosis, or bronchiectasis. Current use of daily inhaled steroids for any condition.

8. Persons with HIV and a detectable HIV viral load (>20 copies/mL), self-reported or confirmed.

9. Administration of monoclonal antibodies for treatment of COVID-19 infection within 3 months.

10. Moderately or severely immunocompromised (e.g. transplant recipients/CAR-T cell therapy, currently on chemotherapy for cancer or on potent immunosuppressant therapies e.g. rituximab or high dose steroids [>30 mg of prednisone equivalent daily], or moderate or severe primary immunodeficiency syndrome).

11. History of severe reaction to previous COVID vaccination (e.g. hives, difficulty breathing, high fever, seizures, myocarditis, pericarditis)).

12. Potential contraindication to COVID vaccination (e.g. venous or arterial thrombosis with thrombocytopenia after vaccination, history of cerebral venous thrombosis with thrombocytopenia, history of heparin induced thrombocytopenia, history of myocarditis or pericarditis).

13. Known allergy to vaccine components or previous receipt of any experimental adenovirus-vector vaccine by the aerosol route.

14. Enrolment in any clinical trial of experimental treatment for COVID infection within 90 days.

15. For participants in the BAL sub-study, any health-related condition for which study bronchoscopy is contraindicated.

16. For participants in the BAL sub-study, current use of anticoagulants.

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Infection

Intervention

Biological:
• ChAd-triCoV/Mac
Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.

Other:
• Control
A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.

Locations

Country	Name	City	State
Canada	Health Sciences Centre	Hamilton	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
McMaster University	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antigen specific T cell responses in blood.	Percentage of cytokine positive T cells in the blood	2 weeks
Primary	Antigen specific T cell responses in bronchoalveolar lavage (BAL).	Percentage of cytokine positive T cells in the BAL	4 weeks
Primary	Any grade 3, 4, or 5 adverse events that are possibly or probably related to study vaccine.	Frequency, incidence and nature of adverse events	24 weeks
Secondary	Confirmed COVID infection by reverse transcriptase polymerase chain reaction (RT-PCR)	Positive RT-PCR test	24 weeks
Secondary	CD4 and CD8 T cell responses specific for the spike (S1), nucleoprotein (N) and polymerase (POL) SARS-CoV-2 antigens expressed by the vaccine, including those expressing memory T cell markers, in the peripheral blood.	Percentage of cytokine positive T cells in the blood to specific antigens	4 and 8 weeks
Secondary	Neutralizing and total antibody levels in BAL and blood	Anti-receptor binding domain (RBD) IgG and IgA endpoint titre; percent neutralization (surrogate virus neutralization test [sVNT])	2, 4 and 8 weeks
Secondary	Any adverse events, including grade 1 or 2 or where relationship to vaccine/placebo administration or study procedures is judged not related or unlikely.	Frequency, incidence and nature of any adverse events	24 weeks
Secondary	Tissue-resident memory surface marker expression airway T cells	Percentage CD103+CD8+ specific cells	4 weeks